Nature cancer最新文献_第4页

Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers 对中国高危前列腺癌样本的综合蛋白质基因组分析表明了代谢脆弱性和诊断生物标志物。

IF 23.5 1区医学

Nature cancer Pub Date : 2024-09-06 DOI: 10.1038/s43018-024-00820-2

Baijun Dong, Jun-Yu Xu, Yuqi Huang, Jiacheng Guo, Qun Dong, Yanqing Wang, Ni Li, Qiuli Liu, Mingya Zhang, Qiang Pan, Hanling Wang, Jun Jiang, Bairun Chen, Danqing Shen, Yiming Ma, Linhui Zhai, Jian Zhang, Jing Li, Wei Xue, Minjia Tan, Jun Qin

{"title":"Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers","authors":"Baijun Dong, Jun-Yu Xu, Yuqi Huang, Jiacheng Guo, Qun Dong, Yanqing Wang, Ni Li, Qiuli Liu, Mingya Zhang, Qiang Pan, Hanling Wang, Jun Jiang, Bairun Chen, Danqing Shen, Yiming Ma, Linhui Zhai, Jian Zhang, Jing Li, Wei Xue, Minjia Tan, Jun Qin","doi":"10.1038/s43018-024-00820-2","DOIUrl":"10.1038/s43018-024-00820-2","url":null,"abstract":"Prostate cancer (PCa) exhibits significant geoethnic disparities as reflected by distinct variations in the cancer genome and disease progression. Here, we perform a comprehensive proteogenomic characterization of localized high-risk PCa utilizing paired tumors and nearby tissues from 125 Chinese male patients, with the primary objectives of identifying potential biomarkers, unraveling critical oncogenic events and delineating molecular subtypes with poor prognosis. Our integrated analysis highlights the utility of GOLM1 as a noninvasive serum biomarker. Phosphoproteomics analysis reveals the crucial role of Ser331 phosphorylation on FOXA1 in regulating FOXA1-AR-dependent cistrome. Notably, our proteomic profiling identifies three distinct subtypes, with metabolic immune-desert tumors (S-III) emerging as a particularly aggressive subtype linked to poor prognosis and BCAT2 catabolism-driven PCa progression. In summary, our study provides a comprehensive resource detailing the unique proteomic and phosphoproteomic characteristics of PCa molecular pathogenesis and offering valuable insights for the development of diagnostic and therapeutic strategies. Dong et al. present an integrative proteogenomic analysis of high-risk prostate cancer samples from a cohort of Chinese patients and highlight potential therapeutic vulnerabilities and diagnostic markers.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"5 9","pages":"1427-1447"},"PeriodicalIF":23.5,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies 癌症患者组织样本和细胞系的蛋白质表达图谱有助于深入了解肿瘤的异质性和依赖性。

IF 23.5 1区医学

Nature cancer Pub Date : 2024-09-03 DOI: 10.1038/s43018-024-00817-x

Jun Li, Wei Liu, Kamalika Mojumdar, Hong Kim, Zhicheng Zhou, Zhenlin Ju, Shwetha V. Kumar, Patrick Kwok-Shing Ng, Han Chen, Michael A. Davies, Yiling Lu, Rehan Akbani, Gordon B. Mills, Han Liang

{"title":"A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies","authors":"Jun Li, Wei Liu, Kamalika Mojumdar, Hong Kim, Zhicheng Zhou, Zhenlin Ju, Shwetha V. Kumar, Patrick Kwok-Shing Ng, Han Chen, Michael A. Davies, Yiling Lu, Rehan Akbani, Gordon B. Mills, Han Liang","doi":"10.1038/s43018-024-00817-x","DOIUrl":"10.1038/s43018-024-00817-x","url":null,"abstract":"The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) are foundational resources in cancer research, providing extensive molecular and phenotypic data. However, large-scale proteomic data across various cancer types for these cohorts remain limited. Here, we expand upon our previous work to generate high-quality protein expression data for approximately 8,000 TCGA patient samples and around 900 CCLE cell line samples, covering 447 clinically relevant proteins, using reverse-phase protein arrays. These protein expression profiles offer profound insights into intertumor heterogeneity and cancer dependency and serve as sensitive functional readouts for somatic alterations. We develop a systematic protein-centered strategy for identifying synthetic lethality pairs and experimentally validate an interaction between protein kinase A subunit α and epidermal growth factor receptor. We also identify metastasis-related protein markers with clinical relevance. This dataset represents a valuable resource for advancing our understanding of cancer mechanisms, discovering protein biomarkers and developing innovative therapeutic strategies. Liang and colleagues establish a high-quality protein expression resource for 8,000 The Cancer Genome Atlas patient samples and 900 Cancer Cell Line Encyclopedia cell lines for approximately 450 proteins, which they use to identify synthetic lethality pairs and metastasis markers.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"5 10","pages":"1579-1595"},"PeriodicalIF":23.5,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting IL-17A to combat immune-related adverse events 以 IL-17A 为靶点，应对免疫相关不良事件。

IF 23.5 1区医学

Nature cancer Pub Date : 2024-08-29 DOI: 10.1038/s43018-024-00804-2

Kailan Sierra-Davidson, Genevieve M. Boland

引用次数: 0

A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma 表达 IL-17A 的 CD4+ T 细胞增多的可靶向 III 型免疫反应与免疫疗法诱导的黑色素瘤毒性有关。

IF 23.5 1区医学

Nature cancer Pub Date : 2024-08-29 DOI: 10.1038/s43018-024-00810-4

Florentia Dimitriou, Phil F. Cheng, Annalisa Saltari, Katrin Schaper-Gerhardt, Ramon Staeger, Veronika Haunerdinger, Federica Sella, Aizhan Tastanova, Christian Urban, Susanne Dettwiler, Daniela Mihic-Probst, Christian M. Matter, Olivier Michielin, Ralf Gutzmer, Georgina V. Long, Burkhard Becher, Mitchell P. Levesque, Reinhard Dummer

{"title":"A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma","authors":"Florentia Dimitriou, Phil F. Cheng, Annalisa Saltari, Katrin Schaper-Gerhardt, Ramon Staeger, Veronika Haunerdinger, Federica Sella, Aizhan Tastanova, Christian Urban, Susanne Dettwiler, Daniela Mihic-Probst, Christian M. Matter, Olivier Michielin, Ralf Gutzmer, Georgina V. Long, Burkhard Becher, Mitchell P. Levesque, Reinhard Dummer","doi":"10.1038/s43018-024-00810-4","DOIUrl":"10.1038/s43018-024-00810-4","url":null,"abstract":"Immune checkpoint inhibitors are standard-of-care for the treatment of advanced melanoma, but their use is limited by immune-related adverse events. Proteomic analyses and multiplex cytokine and chemokine assays from serum at baseline and at the adverse event onset indicated aberrant T cell activity with differential expression of type I and III immune signatures. This was in line with the finding of an increase in the proportion of CD4+ T cells with IL-17A expression at the adverse event onset in the peripheral blood using flow cytometry. Multiplex immunohistochemistry and spatial transcriptomics on immunotherapy-induced skin rash and colitis showed an increase in the proportion of CD4+ T cells with IL-17A expression. Anti-IL-17A was administered in two patients with mild myocarditis, colitis and skin rash with resolution of the adverse events. This study highlights the potential role of type III CD4+ T cells in adverse event development and provides proof-of-principle evidence for a clinical trial using anti-IL-17A for treating adverse events. Dimitriou et al. perform multiomic profiling of patients with melanoma experiencing immunotherapy-associated toxicity and identify a targetable role for type III-associated immune responses with an increase in CD4+ T cells expressing IL-17A.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"5 9","pages":"1390-1408"},"PeriodicalIF":23.5,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s43018-024-00810-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142109652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer 磷酸化 HDAC6 的相分离驱动三阴性乳腺癌染色质结构异常。

IF 23.5 1区医学

Nature cancer Pub Date : 2024-08-28 DOI: 10.1038/s43018-024-00816-y

Bing Lu, Ru Qiu, Jiatian Wei, Li Wang, Qinkai Zhang, Mingsen Li, Xiudan Zhan, Jian Chen, I-Yun Hsieh, Ciqiu Yang, Jing Zhang, Zicheng Sun, Yifan Zhu, Tao Jiang, Han Zhu, Jie Li, Wei Zhao

{"title":"Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer","authors":"Bing Lu, Ru Qiu, Jiatian Wei, Li Wang, Qinkai Zhang, Mingsen Li, Xiudan Zhan, Jian Chen, I-Yun Hsieh, Ciqiu Yang, Jing Zhang, Zicheng Sun, Yifan Zhu, Tao Jiang, Han Zhu, Jie Li, Wei Zhao","doi":"10.1038/s43018-024-00816-y","DOIUrl":"10.1038/s43018-024-00816-y","url":null,"abstract":"How dysregulated liquid–liquid phase separation (LLPS) contributes to the oncogenesis of female triple-negative breast cancer (TNBC) remains unknown. Here we demonstrate that phosphorylated histone deacetylase 6 (phospho-HDAC6) forms LLPS condensates in the nuclei of TNBC cells that are essential for establishing aberrant chromatin architecture. The disordered N-terminal domain and phosphorylated residue of HDAC6 facilitate effective LLPS, whereas nuclear export regions exert a negative dominant effect. Through phase-separation-based screening, we identified Nexturastat A as a specific disruptor of phospho-HDAC6 condensates, which effectively suppresses tumor growth. Mechanistically, importin-β interacts with phospho-HDAC6, promoting its translocation to the nucleus, where 14-3-3θ mediates the condensate formation. Disruption of phospho-HDAC6 LLPS re-established chromatin compartments and topologically associating domain boundaries, leading to disturbed chromatin loops. The phospho-HDAC6-induced aberrant chromatin architecture affects chromatin accessibility, histone acetylation, RNA polymerase II elongation and transcriptional profiles in TNBC. This study demonstrates phospho-HDAC6 LLPS as an emerging mechanism underlying the dysregulation of chromatin architecture in TNBC. Lu et al. investigate the involvement of liquid–liquid phase separation in the progression of triple-negative breast cancer and find that phosphorylated histone deacetylase 6 forms condensates that affect chromatin accessibility and oncogenic transcriptional programs.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"5 11","pages":"1622-1640"},"PeriodicalIF":23.5,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s43018-024-00816-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142093562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial TIGIT-LAG3阻断治疗骨髓瘤后的临床反应和通路特异性相关性：MyCheckpoint随机临床试验。

IF 23.5 1区医学

Nature cancer Pub Date : 2024-08-26 DOI: 10.1038/s43018-024-00818-w

Shambavi Richard, Alexander M. Lesokhin, Barry Paul, Jonathan L. Kaufman, Matthew Pianko, Noa Biran, Ravi Vij, Deon B. Doxie, Maryam I. Azeem, Mercedes Martillo, Katie Wozniak, Hearn J. Cho, Kavita M. Dhodapkar, Madhav V. Dhodapkar

{"title":"Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial","authors":"Shambavi Richard, Alexander M. Lesokhin, Barry Paul, Jonathan L. Kaufman, Matthew Pianko, Noa Biran, Ravi Vij, Deon B. Doxie, Maryam I. Azeem, Mercedes Martillo, Katie Wozniak, Hearn J. Cho, Kavita M. Dhodapkar, Madhav V. Dhodapkar","doi":"10.1038/s43018-024-00818-w","DOIUrl":"10.1038/s43018-024-00818-w","url":null,"abstract":"Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody followed by combination with pomalidomide and dexamethasone ( NCT04150965 ). Primary and secondary endpoints were safety and efficacy, respectively. Therapy was well tolerated without dose-limiting toxicity. Durable clinical responses were observed in both the anti-TIGIT(three of six participants) and the anti-LAG3 (two of six participants) arms. Anti-LAG3 responders had higher naive cluster of differentiation 4 (CD4)-positive T cells and lower programmed cell death protein 1-positive effector T cells. Anti-TIGIT responders had higher CD226 expression, natural killer cell activation and lower CD112 expression. These data demonstrate the clinical activity of TIGIT–LAG3 blockade and identify pathway-specific response correlates in myeloma. Richard et al. perform a clinical trial of anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody in combination with pomalidomide and dexamethasone in persons with multiple myeloma and define correlates of response using mass cytometry.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"5 10","pages":"1459-1464"},"PeriodicalIF":23.5,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comeback for checkpoint inhibition in multiple myeloma 检查点抑制剂在多发性骨髓瘤中卷土重来。

IF 23.5 1区医学

Nature cancer Pub Date : 2024-08-26 DOI: 10.1038/s43018-024-00803-3

Maximilian Merz

引用次数: 0

BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models BRD-810 是一种高选择性 MCL1 抑制剂，具有优化的体内清除率，在实体瘤和血液肿瘤模型中疗效显著。

IF 23.5 1区医学

Nature cancer Pub Date : 2024-08-23 DOI: 10.1038/s43018-024-00814-0

Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T. Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange, Jennifer Roth, Douglas Daniels, Virendar K. Kaushik, Brian Hubbard, Karl Ziegelbauer, Todd R. Golub

{"title":"BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models","authors":"Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T. Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange, Jennifer Roth, Douglas Daniels, Virendar K. Kaushik, Brian Hubbard, Karl Ziegelbauer, Todd R. Golub","doi":"10.1038/s43018-024-00814-0","DOIUrl":"10.1038/s43018-024-00814-0","url":null,"abstract":"The MCL1 gene is frequently amplified in cancer and codes for the antiapoptotic protein myeloid cell leukemia 1 (MCL1), which confers resistance to the current standard of care. Therefore, MCL1 is an attractive anticancer target. Here we describe BRD-810 as a potent and selective MCL1 inhibitor and its key design principle of rapid systemic clearance to potentially minimize area under the curve-driven toxicities associated with MCL1 inhibition. BRD-810 induced rapid cell killing within 4 h in vitro but, in the same 4-h window, had no impact on cell viability or troponin I release in human induced pluripotent stem cell-derived cardiomyocytes, even at suprapharmacologic concentrations. In vivo BRD-810 induced efficacy in xenograft hematological and solid tumor models despite the short residence time of BRD-810 in plasma. In totality, our data support the hypothesis that short-term inhibition of MCL1 with BRD-810 can induce apoptosis in tumor cells while maintaining an acceptable safety profile. We, therefore, intend to advance BRD-810 to clinical trials. Rauh et al. developed a selective MCL1 inhibitor that is efficacious in hematological and solid tumors and has the advantage of limited cardiotoxicity because of more rapid clearance of the drug in vivo.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"5 10","pages":"1479-1493"},"PeriodicalIF":23.5,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11502502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-cell atlas defines distinct immune escape mechanisms in colorectal cancer 单细胞图谱确定了结直肠癌中不同的免疫逃逸机制。

IF 23.5 1区医学

Nature cancer Pub Date : 2024-08-23 DOI: 10.1038/s43018-024-00809-x

引用次数: 0

Dual inhibition of EGFR and PI3K with a single drug 用一种药物同时抑制表皮生长因子受体和 PI3K。

IF 23.5 1区医学

Nature cancer Pub Date : 2024-08-16 DOI: 10.1038/s43018-024-00806-0

Meghri Katerji, Maxine R. Rubin, John Brognard

引用次数: 0